Compare IKT & SY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IKT | SY |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.9M | 276.7M |
| IPO Year | 2020 | 2018 |
| Metric | IKT | SY |
|---|---|---|
| Price | $1.65 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 2 |
| Target Price | $5.55 | ★ $7.31 |
| AVG Volume (30 Days) | ★ 559.3K | 312.6K |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | ★ 1.17% |
| EPS Growth | ★ 57.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $34.60 |
| Revenue Next Year | $33.33 | $36.03 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.33 | $1.28 |
| 52 Week High | $2.61 | $4.75 |
| Indicator | IKT | SY |
|---|---|---|
| Relative Strength Index (RSI) | 25.79 | 33.38 |
| Support Level | $1.59 | $2.18 |
| Resistance Level | $1.74 | $2.38 |
| Average True Range (ATR) | 0.11 | 0.13 |
| MACD | -0.03 | -0.06 |
| Stochastic Oscillator | 4.85 | 4.07 |
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
So-Young International Inc is an aesthetic treatment platform in China connecting consumers with online services and offline treatments. Its online platform operates across multiple access points, including mobile app, Weixin mini program, and soyoung.com website, where both consumers and aesthetic practitioners can access media content, an engaging social community and a transparent reservation system. The company has four reportable segments: Aesthetic treatment services group, Platform service group, Wuhan Miracle, and Others. The majority of revenue is derived from the Platform service group, which generates revenue by providing information services and reservation services. All the company's revenues are derived from within the PRC.